Biomedical subjects

J L Poveda-Andrés

Publications and source records attributed to J L Poveda-Andrés.

2 recordsLinked to original sources

PubMedDate not supplied

[Possible gabapentin phenytoin interaction].

INTRODUCTION: We report a possible case of gabapentin induced phenytoin toxicity. CASE REPORT: White man, 26 years old, chronically treated with phenytoin (for the past 4 years) and gabapentin (for the past 17 months). He was seen after complaining of dysarthria, ataxia and vertigo for the past 3 months, although having noted slight dizziness and a general, though undefined, indisposition from the start of taking gabapentin. The total and free serum levels of phenytoin found were clearly toxic. Gabapentin was discontinued definitively, and phenytoin for the next 7 days. The clinical symptoms had disappeared completely and phenytoin returned to within therapeutic levels. According to the criteria of causation it can be considered a possible adverse reaction caused by phenytoin related to incorporation of gabapentin. The mechanisms of this possible drug interaction are discussed, with emphasis on cytochrome P450 metabolism. CONCLUSION: The present case is a warning of the possible interaction of a drug (gabapentin) not contemplated when starting or when monitoring an antiepileptic treatment.

Acetates↗

PubMedDate not supplied

[Somatostatin stability in parenteral nutrition units].

The incorporation of somatostatin into parenteral nutritional units has considerable advantages in the treatment of patients subjected to this combined therapy with respect to a reduction in the cost of the therapy and an increase in its effectiveness. This study evaluates the stability of somatostatin in "all-in-one" parenteral nutritional units formulated with or without lipids and preserved at 5 or 25 degrees C for a study period of 7 days. The concentration of somatostatin was determined by high resolution liquid chromatography. All the parenteral nutritional units tested remained stable with regard to content in somatostatin for at least 7 days. The t90 values were around 13.3 days for nutritional mixtures without lipids preserved at 5 degrees C, manifesting the positive influence of refrigeration and lipid emulsion on the stability of somatostatin. None of the PNV showed modifications in pH, colour, precipitation or breakage of lipid emulsion during the study period. The above means that somatostatin can be prepared and administered together with Total Parenteral Nutrition in parenteral nutritional units formulated in the same container.

Drug Stability↗